AMACR Detection System Using H2O2 Biosensor

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current prostate cancer screening methods, particularly relying on PSA, face limitations such as non-specificity, over-diagnosis, and over-treatment due to PSA's inability to accurately differentiate between benign conditions and aggressive cancer, leading to unnecessary procedures and anxiety.

Innovation Solution

A detection system and in vitro assay that utilizes a biosensor to quantify alpha-methylacyl-CoA racemase (AMACR) levels in bodily samples by generating hydrogen peroxide through a biochemical pathway, employing a (2R)-2-methylacyl-CoA epimer and peroxisomalacyl-coenzyme A oxidase 3, with nano-particle metallic catalysts to enhance sensitivity and specificity for prostate cancer detection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If PSA screening is used to detect prostate cancer, then early diagnosis is achieved, but false positives occur due to lack of specificity

Engineering Contradiction:

Improvediagnosis accuracyVSAvoidbiomarker specificity

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent introduces AMACR as an intermediary biomarker that specifically targets prostate cancer cells. Unlike PSA which reacts to both benign and malignant conditions, AMACR serves as a selective mediator that indicates the presence of cancerous tissue through its overexpression in prostate cancer epithelium, thereby resolving the specificity problem

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the measured parameter from PSA levels to AMACR expression levels. This parameter change enables differentiation between benign and malignant conditions because AMACR is specifically overexpressed in prostate cancer cells, providing a more precise measurement that reduces false positives

Inventive Principle:

Principle #35Parameter changes

2Productivity

If PSA screening is used to identify prostate cancer cases, then more cases are detected, but over-diagnosis and over-treatment occur

Engineering Contradiction:

Improvecase detection rateVSAvoidclinical significance accuracy

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

AMACR serves as a more reliable intermediary indicator that specifically marks clinically significant prostate cancer. The patent demonstrates that AMACR overexpression correlates with aggressive cancer phenotypes, enabling better identification of cases that truly require intervention versus those that are clinically insignificant

Inventive Principle:

Principle #24Intermediary (Mediator)

3Ease of operation

If traditional PSA testing is performed, then screening is simple and widely applicable, but unnecessary procedures and patient anxiety result

Engineering Contradiction:

Improvescreening accessibilityVSAvoidpatient harm from unnecessary procedures

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The patent introduces AMACR as a superior intermediary biomarker that maintains the simplicity of blood-based testing while dramatically improving diagnostic accuracy. This reduces harmful effects by eliminating unnecessary biopsies and treatments associated with false positive PSA results

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The system provides a cost-effective, minimally invasive method for early detection and monitoring of prostate cancer, distinguishing between healthy and cancerous states with high accuracy, reducing false positives and negatives, and minimizing complications associated with existing screening methods.

Implementation Method 1

an enzyme that carries out beta oxidation with the (2S)-2-methylacyl-CoA epimer to generate hydrogen peroxide (H2O2)

Methodology Applied

Scientific EffectBeta oxidation:

Implementation Method 2

peroxisomalacyl-coenzyme A oxidase 3 (ACOX3)

Methodology Applied

Scientific EffectEnzyme catalysis: Enzyme

Implementation Method 3

peroxisomalacyl-coenzyme A oxidase 3 (ACOX3)

Methodology Applied

Scientific EffectOxidation: Oxidation

Implementation Method 4

catalyst particles that can increase the rate of electrochemical oxidation-reduction reaction with H2O2 and provide for the detection of H2O2

Methodology Applied

Scientific EffectElectrochemical oxidation-reduction reaction: Redox Reactions

Implementation Method 5

catalyst particles that can increase the rate of electrochemical oxidation-reduction reaction with H2O2

Methodology Applied

Scientific EffectCatalysis: Catalysis

Implementation Method 6

The catalyst particles can include nano-particle metallic catalysts

Methodology Applied

Scientific EffectNanoparticle catalysis:

Implementation Method 7

a (2R)-2-methylacyl-CoA epimer that can be chirally inverted by AMACR to a (2S)-2-methylacyl-CoA epimer

Methodology Applied

Scientific EffectChiral inversion:

Implementation Method 8

alpha-methylacyl-CoA racemase (AMACR)

Methodology Applied

Scientific EffectEnzyme catalysis: Enzyme

Data Source

PatentUS10246734B2System and method for detecting alpha-methylacyl-CoA racemase (AMACR) and prostate cancer

Publication Date: 2019.04.02 CASE WESTERN RESERVE UNIV

AI summary

A detection system for determining alpha-methylacyl-CoA (AMACR) levels in a bodily sample includes at least one reaction solution for generating H2O2 upon combination with AMACR in the bodily sample and a biosensor for determining a level of generated H2O2. The reaction solution includes a (2R)-2-methylacyl-CoA epimer that can be chirally inverted by AMACR to a (2S)-2-methylacyl-CoA epimer and an enzyme that carries out beta oxidation with the (2S)-2-methylacyl-CoA epimer to generate hydrogen peroxide (H2O2).